{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Trametinib+1+MG&page=2", "query": { "intervention": "Trametinib 1 MG", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 42, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Trametinib+1+MG&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Trametinib+1+MG&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T18:26:26.177Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02034110", "title": "Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 206, "start_date": "2014-03-12", "completion_date": "2021-12-10", "has_results": true, "last_update_posted_date": "2023-08-21", "last_synced_at": "2026-10-02T18:26:26.177Z", "location_count": 8, "location_summary": "Little Rock, Arkansas • Santa Monica, California • Bethesda, Maryland + 4 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Santa Monica", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02034110" }, { "nct_id": "NCT04903119", "title": "Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma", "BRAF Gene Mutation" ], "interventions": [ { "name": "Nilotinib 100mg", "type": "DRUG" }, { "name": "Nilotinib 200mg", "type": "DRUG" }, { "name": "Nilotinib 300mg", "type": "DRUG" }, { "name": "Nilotinib 400mg", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rina Plattner", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-06-01", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-02T18:26:26.177Z", "location_count": 4, "location_summary": "Iowa City, Iowa • Lexington, Kentucky • Easton, Pennsylvania + 1 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Easton", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04903119" }, { "nct_id": "NCT01725100", "title": "A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "GSK1120212B (Standard DMSO content)", "type": "DRUG" }, { "name": "GSK1120212B (Lower DMSO content)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2013-02-05", "completion_date": "2015-01-30", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-10-02T18:26:26.177Z", "location_count": 4, "location_summary": "Goodyear, Arizona • Scottsdale, Arizona • Sarasota, Florida + 1 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01725100" }, { "nct_id": "NCT03704688", "title": "Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "KRAS Gene Mutation" ], "interventions": [ { "name": "Trametinib 0.5 mg", "type": "DRUG" }, { "name": "Trametinib 1 MG", "type": "DRUG" }, { "name": "Trametinib 1.5 MG", "type": "DRUG" }, { "name": "Trametinib 2 mg", "type": "DRUG" }, { "name": "Ponatinib 15 MG", "type": "DRUG" }, { "name": "Ponatinib 30 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 12, "start_date": "2018-10-09", "completion_date": "2022-02-04", "has_results": true, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-10-02T18:26:26.177Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03704688" }, { "nct_id": "NCT02292173", "title": "Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Cancer", "Liver Cancer" ], "interventions": [ { "name": "Trametinib", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2015-02-18", "completion_date": "2021-01", "has_results": false, "last_update_posted_date": "2021-06-10", "last_synced_at": "2026-10-02T18:26:26.177Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02292173" }, { "nct_id": "NCT02027961", "title": "Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2013-12-20", "completion_date": "2018-04-24", "has_results": false, "last_update_posted_date": "2019-05-17", "last_synced_at": "2026-10-02T18:26:26.177Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02027961" }, { "nct_id": "NCT03972046", "title": "Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)", "Melanoma Stage IIIb-IVM1a", "Metastasis Skin", "Tumor Skin", "BRAF Gene Mutation" ], "interventions": [ { "name": "Talimogene laherparepvec (T-Vec)", "type": "DRUG" }, { "name": "Dabrafenib (BRAF Inhibitor)", "type": "DRUG" }, { "name": "Trametinib (MEK Inhibitor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TriHealth Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-06-24", "completion_date": "2020-02-03", "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-10-02T18:26:26.177Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03972046" }, { "nct_id": "NCT01701037", "title": "Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IIB Melanoma (Locally Advanced)", "Stage IIC Melanoma (Locally Advanced)", "Stage IIIA Melanoma", "Stage IIIB Melanoma", "Stage IIIC Melanoma", "Stage IV Melanoma (Limited, Resectable)" ], "interventions": [ { "name": "dabrafenib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 13, "start_date": "2013-01", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2017-06-23", "last_synced_at": "2026-10-02T18:26:26.177Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01701037" }, { "nct_id": "NCT03501368", "title": "Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Unresectable Melanoma", "Advanced Melanoma" ], "interventions": [ { "name": "Ceritinib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2018-06-27", "completion_date": "2024-12-30", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-02T18:26:26.177Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03501368" }, { "nct_id": "NCT01740648", "title": "Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Rectal Cancer", "Stage IIA Rectal Cancer", "Stage IIB Rectal Cancer", "Stage IIC Rectal Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Rectal Cancer" ], "interventions": [ { "name": "trametinib", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2012-11-26", "completion_date": "2021-09-29", "has_results": false, "last_update_posted_date": "2023-09-18", "last_synced_at": "2026-10-02T18:26:26.177Z", "location_count": 4, "location_summary": "St Louis, Missouri • Buffalo, New York • Columbus, Ohio + 1 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Buffalo", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01740648" } ] }